Anti-EGFR monoclonal antibodies which act as EGF, TGFα, HB-EGF and BTC antagonists block the binding of epiregulin to EGFR-expressing tumours

Sensitivity of Normal, Paramalignant, and Malignant Human Urothelial Cells to Inhibitors of the Epidermal Growth Factor Receptor Signaling Pathway

“…This sensitivity is maintained in cells with p16 loss, and although we found some evidence for reduced sensitivity in cells with disabled p53 function, the UCC-derived cell lines were the most refractory, implying that other desensitizing mechanisms are acquired during malignant progression. The three UCC cell lines, RT4, RT112, and EJ, have previously been shown to express EGFR and are therefore suitable candidates for treatment with EGFR inhibitors (32)(33)(34)(35). Although numerous studies have reported an inhibition of proliferation induced by EGFR tyrosine kinase inhibitors in bladder tumor cell lines (34)(35)(36), few studies have investigated the relative effects of inhibitors on normal and malignant-derived cells.…”

Expression and regulation of c-erbB ligands in human head and neck squamous carcinoma cells

“…Recombinant human HRG-␤1 (amino acids 177-244) was a generous gift from Dr. M. X. Sliwkowski (Genetech, Inc., San Francisco, CA). The rat mAb directed against the extracellular domain of the human EGFR (ICR62) has been described previously (Modjtahedi et al, 1998). The species-specific secondary antibodies coupled to horseradish peroxidase (HRP) and luminol reagents were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).…”

In Silico and in vitro Evaluation of a Recombinant Fusion Peptide as a Novel Candidate Vaccine for EGFR-positive Tumors

“…Plates were washed two times with TBST and blocked with 5% (w/v) skim milk in TBST for 1 h at RT. Blocking buffer discarded and 1µgr anti EGFR antibodies (ICR61, ICR62 (16) and rabbit IgGs against mimotope (14)) added into the wellsand were incubated for 1 h at 37 o C. Wells were washed 5 times with PBST. 100µl of 1/10000 diluted HRP conjugated secondary antibody in PBS (1:10000, v/v) (Pharmacia) was added to the wells and incubated at 37 o C for 1 h. After 5 washes with TBST, 50 µl of TMB ELISA substrate solution (Sigma-Aldrich) was added and incubated for 15 minutes at RT.…”